C

California Neuropsychopharmacology Clinical Research Institute | CNRI San Diego, CA

Research site

Location

5050 Murphy Canyon Rd Ste 100, San Diego, California, United States of America

Site insights

Top conditions

Top treatments

Lurasidone

SEP-363856

Cariprazine

KarXT

BMS-820836

Aripiprazole

RO6889450

Ralmitaront

Lithium

Quetiapine fumarate

Parent organization

This site is a part of California Neuropsychopharmacology Clinical Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

CNRI San Diego, CA

Verified by this site

Active trials

4 of 34 total trials

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely...

Enrolling

Schizophrenia

Drug: SEP-363856

Other: Placebo

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling

Schizophrenia

Drug: Xanomeline and Trospium Chloride Capsules

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major D...

Enrolling

Major Depressive Disorder (MDD)

Drug: Placebo

Drug: Milsaperidone